United States Prosthetic Heart Valves Market Outlook to 2020 - KALB-TV News Channel 5 & CBS 2

United States Prosthetic Heart Valves Market Outlook to 2020

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, May 26, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

United States Prosthetic Heart Valves Market Outlook to 2020

http://www.reportlinker.com/p02127405/United-States-Prosthetic-Heart-Valves-Market-Outlook-to-2020.html

United States Prosthetic Heart Valves Market Outlook to 2020

Summary

GlobalData's new report, "United States Prosthetic Heart Valves Market Outlook to 2020", provides key market data on the United States Prosthetic Heart Valves market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Mechanical Heart Valves, Tissue Heart Valves and Transcatheter Heart Valves.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Prosthetic Heart Valves market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size for Prosthetic Heart Valves categories - Mechanical Heart Valves, Tissue Heart Valves and Transcatheter Heart Valves.
- Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
- 2012 company shares and distribution shares data for the market category.
- Global corporate-level profiles of key companies operating within the United States Prosthetic Heart Valves market.
- Key players covered include Edwards Lifesciences Corporation, Medtronic, Inc., St. Jude Medical, Inc., Sorin Group and CryoLife, Inc.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

1 Table of Contents

2 Introduction 8
2.1 What Is This Report About? 8
2.2 Prosthetic Heart Valves Market Segmentation 8
2.3 Definitions of Markets Covered in the Report 9
3 Prosthetic Heart Valves Market, United States 10
3.1 Prosthetic Heart Valves Market, United States, Revenue ($m), 2005-2012 10
3.2 Prosthetic Heart Valves Market, United States, Revenue ($m), 2012-2020 12
3.2.1 Mechanical Heart Valves Market, United States, Revenue ($m), by Segment, 2005-2012 14
3.2.2 Tissue Heart Valves Market, United States, Revenue ($m), by Segment, 2005-2012 16
3.2.3 Mechanical Heart Valves Market, United States, Revenue ($m), by Segment, 2012-2020 18
3.2.4 Tissue Heart Valves Market, United States, Revenue ($m), by Segment, 2012-2020 20
3.3 Prosthetic Heart Valves Market, United States, Volume (Units), 2005-2012 22
3.4 Prosthetic Heart Valves Market, United States, Volume (Units), 2012-2020 24
3.4.1 Mechanical Heart Valves Market, United States, Volume (Units), by Segment, 2005-2012 26
3.4.2 Tissue Heart Valves Market, United States, Volume (Units), by Segment, 2005-2012 28
3.4.3 Mechanical Heart Valves Market, United States, Volume (Units), by Segment, 2012-2020 30
3.4.4 Tissue Heart Valves Market, United States, Volume (Units), by Segment, 2012-2020 32
3.5 Prosthetic Heart Valves Market, United States, Average Price ($), 2005-2020 34
3.6 Prosthetic Heart Valves Market, United States, Distribution Share by Revenue ($m), 2011-2012 36
3.7 Prosthetic Heart Valves Market, United States, Company Share by Revenue ($m), 2011-2012 37
4 Overview of Key Companies in United States, Prosthetic Heart Valves Market 39
4.1 Edwards Lifesciences Corporation 39
4.1.1 Company Overview 39
4.2 Medtronic, Inc. 39
4.2.1 Company Overview 39
4.3 St. Jude Medical, Inc. 39
4.3.1 Company Overview 39
4.4 Sorin S.p.A. 40
4.4.1 Company Overview 40
5 Prosthetic Heart Valves Market Pipeline Products 41
6 Financial Deals Landscape 42
6.1 Debt Offerings 42
6.1.1 Medtronic Completes Public Offering Of Notes Due 2017 For US$250 Million 42
6.1.2 Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For US$250 Million 44
6.1.3 Medtronic Completes Public Offering Of Notes Due 2024 For US$850 Million 46
6.1.4 Medtronic Completes Public Offering Of Notes Due 2044 For US$650 Million 48
6.1.5 Edwards Lifesciences Completes Public Offering Of Notes Due 2018 For US$600 Million 50
6.1.6 St. Jude Medical Completes Public Offering Of Notes Due 2023 For US$900 Million 52
6.1.7 St. Jude Medical Completes Public Offering Of Notes Due 2043 For US$700 Million 54
6.1.8 Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion 56
6.1.9 Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million 58
6.1.10 Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 60
6.2 Partnerships 62
6.2.1 NeoChord Enters Into Licensing Agreement With Robarts Research Institute 62
6.3 Venture Financing 63
6.3.1 CorMatrix Cardiovascular Raises US$0.25 Million In Venture Financing 63
6.3.2 Cardiaq Valve Technologies Raises US$32.5 Million In Venture Financing 64
7 Recent Developments 65
7.1 Corporate Communications 65
7.1.1 Apr 08, 2014: CardiAQ Valve Technologies appoints Paul Cornelison as Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs 65
7.1.2 Jan 28, 2014: St. Jude Medical Announces Organizational and Executive Leadership Changes 65
7.1.3 Jan 07, 2014: Simbionix Welcomes New Latin and Central American Sales Manager 66
7.1.4 Dec 05, 2013: Anxious Patient Group Calls on NICE to Approve Only Drug Treatment for Ultra-Rare Disease 66
7.1.5 Dec 05, 2013: Edwards Lifesciences Announces Appointment of CFO 68
7.1.6 Nov 04, 2013: Canbex Therapeutics Commences Phase I Clinical Trial of Lead Product VSN16R as a Potential Treatment for Spasticity in Multiple Sclerosis 69
7.1.7 Aug 13, 2013: Covidien launches Barrx Channel RFA Endoscopic Catheter 69
7.1.8 Aug 02, 2013: China CDC Enters Into R&D Agreement With Aeras Global For TB Vaccine 70
7.1.9 Jul 22, 2013: St. Jude Medical Appoints Stefan Widensohler to Its Board of Directors 71
7.1.10 Jul 03, 2013: Novartis Files Patent Infringement Lawsuit Against Intas Pharma Over Generic Myfortic 71
7.1.11 May 14, 2013: Edwards Lifesciences CFO Thomas M Abate To Retire 72
7.1.12 May 08, 2013: Cardio3 BioSciences Raises US$9 Million In Series D Financing 72
7.2 Financial Announcements 74
7.2.1 Apr 24, 2014: Edwards Lifesciences Reports Strong First Quarter Results 74
7.2.2 Apr 16, 2014: St. Jude Medical Reports First Quarter 2014 Results 75
7.2.3 Feb 18, 2014: Medtronic Reports Third Quarter Earnings 77
7.2.4 Feb 03, 2014: Edwards Lifesciences Reports Strong Fourth Quarter Results 79
7.2.5 Jan 22, 2014: St. Jude Medical Reports Fourth Quarter and Full-Year 2013 Results 81
7.2.6 Dec 09, 2013: St. Jude Medical Announces Fourth Quarter Dividend 83
7.2.7 Nov 26, 2013: FDA approves Varithena (polidocanol injectable foam) for the treatment of patients with varicose veins 83
7.2.8 Nov 19, 2013: Medtronic Reports Second Quarter Earnings 84
7.2.9 Nov 11, 2013: Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2014 86
7.2.10 Oct 28, 2013: Edwards Lifesciences Reports Solid Third Quarter Results 86
7.2.11 Oct 16, 2013: St. Jude Medical Reports Third Quarter 2013 Results 88
7.2.12 Oct 02, 2013: St. Jude Medical Announces Third Quarter 2013 Earnings Conference Call 90
7.2.13 Aug 20, 2013: Medtronic Reports First Quarter Earnings 90
7.2.14 Aug 12, 2013: Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2014 92
7.2.15 Jul 30, 2013: Teleflex subsidiary receives 510(k) clearance for balloon dilatation catheters 92
7.2.16 Jul 30, 2013: St. Jude Medical Announces Third Quarter Dividend 93
7.2.17 Jul 25, 2013: Edwards Lifesciences Reports Solid Second Quarter Results 94
7.2.18 Jul 17, 2013: St. Jude Medical Reports Second Quarter 2013 Results 95
7.2.19 Jul 11, 2013: Edwards Lifesciences to Host Earnings Conference Call on July 25, 2013 97
7.2.20 Jul 02, 2013: St. Jude Medical Announces Second Quarter 2013 Earnings Conference Call 97
7.2.21 May 21, 2013: Medtronic Reports Revenue Of $16.6 Billion In Fiscal 2013 97
7.2.22 May 10, 2013: New Excimer Laser from ZEISS for Refractive Surgery Reduces Treatment Time to the Benefit Both Doctor and Patient 99
7.3 Government and Public Interest 101
7.3.1 Mar 11, 2014: Simbionix Provides Comprehensive Virtual Reality Training for the Fast Arthroscopy Curriculum 101
7.3.2 Jan 06, 2014: Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference 101
7.3.3 Dec 18, 2013: St. Jude Medical to Present at the 32nd Annual J.P. Morgan Healthcare Conference 101
7.3.4 Dec 10, 2013: Collaboration Between Simbionix And 1st MSMU To Integrate A Russian Developed Assessment System To Enhance Laparoscopic Training 102
7.3.5 Dec 04, 2013: Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference 102
7.3.6 Nov 26, 2013: Medtronic EVP & President Mike Coyle to Speak at Piper Jaffray Healthcare Conference 102
7.3.7 Nov 21, 2013: St. Jude Medical to Present at the Piper Jaffray 25th Annual Healthcare Conference 103
7.3.8 Nov 06, 2013: St. Jude Medical to Present at the 2013 Credit Suisse Healthcare Conference 103
7.3.9 Nov 01, 2013: St. Jude Medical to Present at the 2013 Credit Suisse Healthcare Conference 103
7.3.10 Oct 28, 2013: Edwards Lifesciences to Webcast Analyst Meeting at TCT 25 103
7.3.11 Oct 14, 2013: Edwards Lifesciences to Host Earnings Conference Call on October 28, 2013 103
7.3.12 Sep 06, 2013: Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference 103
7.3.13 Sep 04, 2013: St. Jude Medical to Present at the Stifel Healthcare Conference 103
7.3.14 Sep 03, 2013: St. Jude Medical to Present at the Morgan Stanley Global Healthcare Conference 104
7.3.15 Aug 12, 2013: Edwards Lifesciences to Present at the Canaccord Genuity Growth Conference 104
7.4 Legal And Regulatory 104
7.4.1 Apr 11, 2014: Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's Infringing Transcatheter Valve 104
7.4.2 Mar 12, 2014: Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test 104
7.4.3 Jan 22, 2014: Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures 105
7.4.4 Nov 14, 2013: Edwards Comments on German Appellate Court Ruling 105
7.4.5 Nov 07, 2013: Law Office of Brodsky & Smith Announces Investigation of Edwards Lifescience 106
7.4.6 Oct 19, 2013: Medtronic Statement on Medical Device Security 106
7.4.7 Oct 18, 2013: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Edwards Lifesciences Corporation 107
7.4.8 Aug 01, 2013: Medtronic Notifies More Than 2,700 Patients Of Lost Records 107
7.4.9 Jul 01, 2013: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Medtronic, Inc. 107
7.5 Other Significant Developments 108
7.5.1 Feb 24, 2014: St. Jude Medical Announces Increase in Quarterly Dividend 108
7.5.2 Feb 13, 2014: Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014 108
7.5.3 Jan 28, 2014: Medtronic Relocates Its Regional Headquarters to Dubai 108
7.5.4 Dec 09, 2013: Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference 109
7.5.5 Dec 06, 2013: The Edwards Lifesciences Fund to Grant ~$5.6 Million to 450+ Non-Profit Organizations in 2013 111
7.5.6 Dec 04, 2013: Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles 111
7.5.7 Aug 22, 2013: Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2014 113
7.6 Product News 113
7.6.1 Mar 31, 2014: Study of transcatheter pulmonary valve shows strong results, reports U-M pediatric interventional cardiologist 113
7.6.2 Dec 27, 2013: Mymetics Enters Into Licensing Agreement With RSV For Respiratory Syncytial Virus Vaccine 114
7.6.3 Nov 18, 2013: Simbionix New ANGIO Mentor Suite Promotes Endovascular Team Training in a True-to-Life Clinical Environment 116
7.6.4 Nov 15, 2013: FDA Classifies Medtronic's Worldwide Voluntary Field Action on Guidewires as Class I Recall 117
7.6.5 Nov 14, 2013: Endovascular Aneurysm Training Module Now Supports Vascutek's Anaconda Devices 117
7.7 Strategy And Business Planning 118
7.7.1 Nov 13, 2013: Edwards Lifesciences Expands Singapore Manufacturing Facility 118
7.7.2 Sep 17, 2013: Medtronic Opens New Customer Innovation Centre in Galway, Ireland 119
7.7.3 Sep 02, 2013: Medtronic announces formation of hospital solutions business aimed at driving efficiencies 120
7.7.4 Aug 29, 2013: Medtronic To Set Up Global Center Of Excellence In Singapore For Business Model Innovation 121
8 Appendix 122
8.1 Research Methodology 123
8.1.1 Coverage 123
8.1.2 Secondary Research 123
8.1.3 Primary Research 124
8.1.4 Market Modeling and Forecasting 125
8.1.5 Company Share Analysis 128
8.1.6 Distribution Share Analysis 129
8.2 Expert Panel 130
8.3 GlobalData Consulting 130
8.4 Contact Us 130
8.5 Disclaimer 130

1.1 List of Tables
Table 1: Prosthetic Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 11
Table 2: Prosthetic Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 13
Table 3: Mechanical Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 15
Table 4: Tissue Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 17
Table 5: Mechanical Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 19
Table 6: Tissue Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 21
Table 7: Prosthetic Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 23
Table 8: Prosthetic Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 25
Table 9: Mechanical Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 27
Table 10: Tissue Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 29
Table 11: Mechanical Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 31
Table 12: Tissue Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 33
Table 13: Prosthetic Heart Valves Market, United States, Average Price ($), Historic, 2005-2012 34
Table 14: Prosthetic Heart Valves Market, United States, Average Price ($), Forecast, 2012-2020 35
Table 15: Prosthetic Heart Valves Market, United States, Distribution Share by Revenue ($m), USD Constant, 2011-2012 36
Table 16: Prosthetic Heart Valves Market, United States, Company Share by Revenue ($m), USD Constant, 2011-2012 38
Table 17: Prosthetic Heart Valves Market Pipeline Products 41
Table 18: Medtronic Completes Public Offering Of Notes Due 2017 For US$250 Million 42
Table 19: Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For US$250 Million 44
Table 20: Medtronic Completes Public Offering Of Notes Due 2024 For US$850 Million 46
Table 21: Medtronic Completes Public Offering Of Notes Due 2044 For US$650 Million 48
Table 22: Edwards Lifesciences Completes Public Offering Of Notes Due 2018 For US$600 Million 50
Table 23: St. Jude Medical Completes Public Offering Of Notes Due 2023 For US$900 Million 52
Table 24: St. Jude Medical Completes Public Offering Of Notes Due 2043 For US$700 Million 54
Table 25: Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion 56
Table 26: Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million 58
Table 27: Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion 60
Table 28: NeoChord Enters Into Licensing Agreement With Robarts Research Institute 62
Table 29: CorMatrix Cardiovascular Raises US$0.25 Million In Venture Financing 63
Table 30: Cardiaq Valve Technologies Raises US$32.5 Million In Venture Financing 64
Table 31: Total Number of Primary Research Participants, Cardiovascular Devices Market, by Country 125

1.2 List of Figures
Figure 1: Prosthetic Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 10
Figure 2: Prosthetic Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 12
Figure 3: Mechanical Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 14
Figure 4: Tissue Heart Valves Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 16
Figure 5: Mechanical Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 18
Figure 6: Tissue Heart Valves Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 20
Figure 7: Prosthetic Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 22
Figure 8: Prosthetic Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 24
Figure 9: Mechanical Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 26
Figure 10: Tissue Heart Valves Market, United States, Volume (Units), Historic, 2005-2012 28
Figure 11: Mechanical Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 30
Figure 12: Tissue Heart Valves Market, United States, Volume (Units), Forecast, 2012-2020 32
Figure 13: Prosthetic Heart Valves Market, United States, Company Share (%), 2012 37
Figure 14: GlobalData Epidemiology-Based Forecasting Model 127
Figure 15: GlobalData Capital Equipment-Based Forecasting Model 128
Figure 16: Primary Interviews by Participant Type (%) 129

To order this report: United States Prosthetic Heart Valves Market Outlook to 2020
http://www.reportlinker.com/p02127405/United-States-Prosthetic-Heart-Valves-Market-Outlook-to-2020.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KALB. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.